Randomized controlled trials (RCT) have described a reduction of monthly migraine days (MMD) of ≥50% at 3 months in up to 62% of patients with EM, and in up to 41% of patients with CM treated with CGRP ligand or receptor mAbs, respectively (4–11). This evidence concerns the gene CALCA and erythema multiforme.